

# Peter Steinwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3150856/publications.pdf>

Version: 2024-02-01

12  
papers

25  
citations

2258059

3  
h-index

2550090

3  
g-index

12  
all docs

12  
docs citations

12  
times ranked

68  
citing authors

#	ARTICLE	IF	CITATIONS
1	Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e312-e314.	1.9	6
2	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 148-154.	1.9	7
3	Circulating tumor DNA (ctDNA) landscape in metastatic castrate-resistant prostate cancer patients with germline alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 200-200.	1.6	0
4	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2019, 19, 524.	2.6	12
5	Evaluation of circulating tumor DNA (ctDNA) with respect to germline alterations in metastatic castrate resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 254-254.	1.6	0
6	Aberrations in androgen receptor ctDNA varies by race in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 247-247.	1.6	0
7	TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 249-249.	1.6	0
8	ctDNA and copy-number variant quantification in mCRPC at the time of progression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 265-265.	1.6	0
9	cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.. <i>Journal of Clinical Oncology</i> , 2018, 36, 256-256.	1.6	0
10	cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 263-263.	1.6	0
11	Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 261-261.	1.6	0
12	Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 255-255.	1.6	0